Upc2-mediated mechanisms of azole resistance in Candida auris

Candida auris is an emerging yeast pathogen of major concern because of its ability to cause hospital outbreaks of invasive candidiasis and to develop resistance to antifungal drugs. A majority of C. auris isolates are resistant to fluconazole, a first-line treatment of invasive candidiasis. Mechanisms of azole resistance are multiple, including mutations in the target gene ERG11 and activation of the transcription factors Tac1b and Mrr1, which control the drug transporters Cdr1 and Mdr1, respectively. In this study, we investigated the role the transcription factor Upc2, which is known to regulate the ergosterol biosynthesis pathway and azole resistance in other Candida spp. Genetic deletion and hyperactivation of Upc2 by epitope tagging in C. auris resulted in drastic increased and decreased susceptibility to azoles, respectively. This effect was conserved in strains with genetic hyperactivation of Tac1b or Mrr1. Reverse transcription PCR analyses showed that Upc2 regulates ERG11 expression and also activates the Mrr1/Mdr1 pathway. We showed that upregulation of MDR1 by Upc2 could occur independently from Mrr1. The impact of UPC2 deletion on MDR1 expression and azole susceptibility in a hyperactive Mrr1 background was stronger than that of MRR1 deletion in a hyperactive Upc2 background. While Upc2 hyperactivation resulted in a significant increase of expression of TAC1b, CDR1 expression remained unchanged. Taken together, our results showed that Upc2 is crucial for azole resistance in C. auris, via regulation of the ergosterol biosynthesis pathway and activation of the Mrr1/Mdr1 pathway. Notably, Upc2 is a very potent and direct activator of Mdr1.

[1]  B. Vu,et al.  Nonidentical function of Upc2A binding sites in the Candida glabrata CDR1 promoter. , 2022, Genetics.

[2]  D. Sanglard,et al.  Deciphering the Mrr1/Mdr1 Pathway in Azole Resistance of Candida auris , 2022, Antimicrobial agents and chemotherapy.

[3]  D. Sanglard,et al.  Novel ERG11 and TAC1b Mutations Associated with Azole Resistance in Candida auris , 2021, Antimicrobial Agents and Chemotherapy.

[4]  A. Chakrabarti,et al.  Multidrug-resistant Candida auris: an epidemiological review , 2020, Expert review of anti-infective therapy.

[5]  S. Kelly,et al.  Comparative Genomics for the Elucidation of Multidrug Resistance in Candida lusitaniae , 2019, mBio.

[6]  W. S. Moye-Rowley,et al.  Evidence that Ergosterol Biosynthesis Modulates Activity of the Pdr1 Transcription Factor in Candida glabrata , 2019, mBio.

[7]  A. Borman,et al.  Candida auris Isolates of the Southern Asian and South African Lineages Exhibit Different Phenotypic and Antifungal Susceptibility Profiles In Vitro , 2019, Journal of Clinical Microbiology.

[8]  Yong Jun Kwon,et al.  Candida auris Clinical Isolates from South Korea: Identification, Antifungal Susceptibility, and Genotyping , 2019, Journal of Clinical Microbiology.

[9]  K. Barker,et al.  Abrogation of Triazole Resistance upon Deletion of CDR1 in a Clinical Isolate of Candida auris , 2019, Antimicrobial Agents and Chemotherapy.

[10]  Brendan R. Jackson,et al.  Molecular Epidemiology of Candida auris in Colombia Reveals a Highly Related, Countrywide Colonization With Regional Patterns in Amphotericin B Resistance , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  A. Chowdhary,et al.  A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009–17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance , 2018, The Journal of antimicrobial chemotherapy.

[12]  D. Hogan,et al.  Use of RNA-Protein Complexes for Genome Editing in Non-albicans Candida Species , 2017, mSphere.

[13]  Christina A. Cuomo,et al.  Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  P. D. Rogers,et al.  Azole Resistance in Candida glabrata , 2016, Current Infectious Disease Reports.

[15]  S. G. Chadwick,et al.  UPC2A Is Required for High-Level Azole Antifungal Resistance in Candida glabrata , 2014, Antimicrobial Agents and Chemotherapy.

[16]  J. Morschhäuser,et al.  Analysis of a fungus‐specific transcription factor family, the Candida albicans zinc cluster proteins, by artificial activation , 2013, Molecular microbiology.

[17]  G. Boucher,et al.  Regulation of Efflux Pump Expression and Drug Resistance by the Transcription Factors Mrr1, Upc2, and Cap1 in Candida albicans , 2011, Antimicrobial Agents and Chemotherapy.

[18]  Hironobu Nakayama,et al.  Transcription factors CgUPC2A and CgUPC2B regulate ergosterol biosynthetic genes in Candida glabrata , 2011, Genes to cells : devoted to molecular & cellular mechanisms.

[19]  F. Robert,et al.  Genomewide Location Analysis of Candida albicans Upc2p, a Regulator of Sterol Metabolism and Azole Drug Resistance , 2008, Eukaryotic Cell.

[20]  Junqing Shen,et al.  CaNAT1, a Heterologous Dominant Selectable Marker for Transformation of Candida albicans and Other Pathogenic Candida Species , 2005, Infection and Immunity.

[21]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.